Story
Changchun High-tech Unit Gets Approval for Osteoporosis Drug Clinical Trial in China
Changchun High-tech Industries (Group) Inc. (000661.SZ) announced that its subsidiary has received approval from Chinese regulators to begin clinical trials for GenSci133, a new injectable drug candidate for treating osteoporosis. The green light was granted by China's National Medical Products Administration (NMPA).
Trial Approval Details
In a corporate filing, the company confirmed that its controlling subsidiary, Changchun Jinsai Pharmacy Co., Ltd., received the formal “Drug Clinical Trial Approval Notice.” This regulatory milestone permits Jinsai Pharmacy to proceed with domestic clinical trials required for the drug's registration in China.
About the Drug Candidate
GenSci133 is a novel, self-developed treatment classified by regulators as a Category 1 therapeutic biological product. The company describes it as a fusion protein that combines two mechanisms of action.
AdSpecifically, it is composed of a parathyroid hormone (PTH) analog and an anti-RANKL (receptor activator of nuclear factor kappa-B ligand) antibody. Its proposed therapeutic indication is for the treatment of osteoporosis, a medical condition that causes bones to become weak and brittle.
Strategic Implications
According to Changchun High-tech, the successful advancement of GenSci133 through clinical trials would be a significant development. A positive outcome is expected to help the company broaden its business, optimize its product portfolio, and enrich its pipeline within the endocrine and metabolic disease sector.
The company stated that this progress, if the trials are successful, would ultimately enhance its core competitiveness in the pharmaceutical market.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.